Clinical Trial Search

Phase 3 N=360 MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin

Diabetes Mellitus, Type 2

Primary: HbA1c Change From Baseline After 24 Weeks Double-blind Randomized Treatment — -0.03; -0.63 Percentage of HbA1c — p=<0.0001

Boehringer Ingelheim Results Mar 2017 6.9% serious AE View details

Phase 3 N=219 Safety and Efficacy Study for Reverse Flow Used During Carotid Artery Stenting Procedure

Carotid Artery Disease

Primary: Hierarchical Composite of Stroke, Myocardial Infarction, and Death — 8 Participants

Silk Road Medical Results Mar 2017 13.2% serious AE View details

Phase 3 N=763 Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis

Dermatitis, Atopic

Primary: Percentage of Participants Who Achieved Treatment Success Based on Investigator's Static Global Assessment (ISGA) at Day 29 — 32.8; 25.4 percentage of participants…

Pfizer Results Mar 2017 0.8% serious AE View details

Phase 3 N=1,482 Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)

Rhinitis, Allergic, Perennial · Rhinitis, Allergic, Nonseasonal

Primary: Average Total Combined Rhinitis Score (TCRS) During Last 8 Weeks of Treatment — 4.67; 5.49 Score on a Scale — p=<0.001

ALK-Abelló A/S Results Mar 2017 1.2% serious AE View details

Phase 3 N=282 Exalenz Lab Mode System Compared to Biopsy for H.Pylori Detection

Helicobacter Pylori Infection

Primary: Sensitivity is Described as the Accuracy of the Breath Test in Detecting H.Pylori Infection Compared to Biopsy — 98.32; 98.53 Percent positive agreement

Meridian Bioscience, Inc. Results Mar 2017 0.0% serious AE View details

Phase 3 N=1,168 Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Prostate Cancer

Primary: Overall Survival (OS) — 24.3; 24.5; 25.2 months — p=0.7574

Sanofi Results Mar 2017 38.5% serious AE View details

Phase 3 N=2,463 Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women

Osteoporosis · Postmenopausal Osteoporosis

Primary: Number of Participants With New Vertebral Fractures at 18 Months — 30; 4; 6 participants — p=<0.0001

Radius Health, Inc. Results Mar 2017 10.2% serious AE View details

Phase 3 N=540 A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

Primary: Overall Survival (OS) — 9.5; 9.5 months — p=0.1343

Eisai Inc. Results Mar 2017 33.9% serious AE View details

Phase 3 N=280 Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy

Mantle Cell Lymphoma

Primary: Progression Free Survival (PFS) — 15.6; 6.2 Months — p=< 0.0001

Janssen Research & Development, LLC Results Mar 2017 58.3% serious AE View details

Phase 3 N=9,340 Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

Diabetes · Diabetes Mellitus, Type 2

Primary: Time From Randomisation to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) — 13.0…

Novo Nordisk A/S Results Mar 2017 50.0% serious AE View details

Phase 3 N=168 Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects

Infections, Meningococcal

Primary: Number of Subjects With Serum Bactericidal Assay Against N. Meningitidis Serogroups A, C Using Rabbit Complement (rSBA-MenA,C) Antibodies — 65; 59; 30; 66 Subjects

GlaxoSmithKline Results Mar 2017 1.8% serious AE View details